Massachusetts Financial Services Co. MA Increases Stock Position in Qiagen N.V. $QGEN

Key Points

• Massachusetts Financial Services Co. MA raised its stake in Qiagen by 1.1% in Q4 to 24,205,881 shares—about 11.46% of the company, worth roughly $1.09 billion after buying 264,921 shares.
• Qiagen beat Q4 estimates, reporting $0.62 EPS vs. $0.61 expected and $540.42M revenue vs. $528.53M, set FY2026 guidance around 2.50 EPS (analysts project ~2.26) and carries a consensus rating of "Hold" with a $55.20 average price target.
• Institutional ownership is high (about 70%), and the stock trades near $40.90 with a market cap of $8.43B and a one‑year range of $38.79–$57.81, indicating mixed momentum despite analyst divergence.

Massachusetts Financial Services Co. MA lifted its holdings in shares of Qiagen N.V. (NYSE:QGEN - Free Report) by 1.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,205,881 shares of the company's stock after buying an additional 264,921 shares during the quarter. Massachusetts Financial Services Co. MA owned about 11.46% of Qiagen worth $1,088,538,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the business. Johnson Investment Counsel Inc. lifted its stake in shares of Qiagen by 0.4% during the 3rd quarter. Johnson Investment Counsel Inc. now owns 57,359 shares of the company's stock valued at $2,563,000 after buying an additional 240 shares in the last quarter. Allworth Financial LP lifted its stake in shares of Qiagen by 23.2% during the 3rd quarter. Allworth Financial LP now owns 1,358 shares of the company's stock valued at $61,000 after buying an additional 256 shares in the last quarter. Bessemer Group Inc. lifted its stake in shares of Qiagen by 0.5% during the 3rd quarter. Bessemer Group Inc. now owns 51,780 shares of the company's stock valued at $2,288,000 after buying an additional 262 shares in the last quarter. Covestor Ltd lifted its stake in shares of Qiagen by 13.6% during the 3rd quarter. Covestor Ltd now owns 3,007 shares of the company's stock valued at $134,000 after buying an additional 361 shares in the last quarter. Finally, Private Advisor Group LLC lifted its stake in shares of Qiagen by 7.1% during the 3rd quarter. Private Advisor Group LLC now owns 5,730 shares of the company's stock valued at $256,000 after buying an additional 378 shares in the last quarter. 70.00% of the stock is currently owned by hedge funds and other institutional investors.

Qiagen Stock Performance

NYSE QGEN opened at $40.90 on Friday. Qiagen N.V. has a 1 year low of $38.79 and a 1 year high of $57.81. The company has a debt-to-equity ratio of 0.44, a current ratio of 3.90 and a quick ratio of 3.31. The stock has a market capitalization of $8.43 billion, a PE ratio of 20.28, a P/E/G ratio of 2.12 and a beta of 0.79. The company's 50 day simple moving average is $45.06 and its two-hundred day simple moving average is $47.67.

Qiagen (NYSE:QGEN - Get Free Report) last posted its earnings results on Wednesday, February 4th. The company reported $0.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.61 by $0.01. The business had revenue of $540.42 million for the quarter, compared to analysts' expectations of $528.53 million. Qiagen had a net margin of 20.33% and a return on equity of 14.56%. The business's revenue for the quarter was up 3.6% compared to the same quarter last year. During the same period in the prior year, the company posted $0.61 EPS. Qiagen has set its FY 2026 guidance at 2.500- EPS and its Q1 2026 guidance at 0.540- EPS. Analysts predict that Qiagen N.V. will post 2.26 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently commented on QGEN shares. Robert W. Baird set a $53.00 price target on shares of Qiagen in a research note on Friday, February 6th. Citigroup lowered their target price on shares of Qiagen from $55.40 to $55.00 and set a "neutral" rating on the stock in a research note on Friday, February 6th. Deutsche Bank Aktiengesellschaft upgraded shares of Qiagen from a "hold" rating to a "buy" rating and set a $54.00 target price on the stock in a research note on Friday, March 13th. Weiss Ratings reiterated a "hold (c)" rating on shares of Qiagen in a research note on Friday, March 27th. Finally, Barclays set a $58.00 target price on shares of Qiagen and gave the stock an "overweight" rating in a research note on Friday, February 6th. Five analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $55.20.

About Qiagen

Qiagen NV NYSE: QGEN is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company's solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company's product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.